Curis, Inc. Aktie News
1,49 $
0,67 %
gestern
Nasdaq,
30. Oktober, 21:00 Uhr
tracken
Curis, Inc. Aktie News
Neutral
PRNewsWire
●
etwa 5 Stunden alt
LEXINGTON, Mass. , Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m.
Neutral
PRNewsWire
●
27 Tage alt
LEXINGTON, Mass. , Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on October 1, 2025, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 84,750...
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Curis, Inc. (NASDAQ:CRIS ) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Presentation Li Wang Watsek Research Analyst Hey, everyone. Welcome to our next session with Curis.
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Curis, Inc. (NASDAQ:CRIS ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 10:00 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Presentation James Dentzer President, CEO, Secretary, Treasurer & Director Good afternoon.
Neutral
PRNewsWire
●
etwa 2 Monate alt
LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Global Healthcare Conference 2025 being held Sep...
Positiv
The Motley Fool
●
3 Monate alt
Curis (CRIS 4.38%), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $0.68 per share, outperforming the analyst expectation of a $1.36 GAAP loss.
Neutral
Seeking Alpha
●
3 Monate alt
Curis, Inc. (NASDAQ:CRIS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Ahmed M. Hamdy - Chief Medical Officer Diantha Duvall - CFO and Principal Financial & Accounting Officer James E.
Neutral
PRNewsWire
●
3 Monate alt
Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
